Opaleye Management’s Kite Pharma, Inc. KITE Stock Holding History

Opaleye Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-76,000	Closed	-$4.38M	–	51
2015 Q1	$4.38M	Hold	76,000	–	–	2.04%	23
2014 Q4	$4.38M	Buy	+76,000	New	+$3.2M	2.21%	16

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Opaleye Management's KITE Position: Q2 2015 in Review

Opaleye Management sold out of Kite Pharma, Inc. (KITE) in Q2 2015, closing a stake of 76,000 shares — an estimated $4.38M sold.

Opaleye Management first reported a position in KITE in Q4 2014 and held it in 2 quarters. The position peaked at $4.38M in Q1 2015. 155 funds tracked by Wall St. Rank hold KITE as of Q2 2015.

Opaleye Management reported no remaining Kite Pharma, Inc. position as of Q2 2015 after selling out during the quarter.
Opaleye Management sold 76,000 Kite Pharma, Inc. shares in Q2 2015, an estimated $4.38M.
Opaleye Management first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 2 quarters.
Opaleye Management's Kite Pharma, Inc. position peaked at $4.38M in Q1 2015.
155 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2015.

Based on Opaleye Management's 13F filing for Q2 2015, filed 14 Aug 2015.